ValiRx PLC

EAJF

Company Profile

  • Business description

    ValiRx PLC is a UK-based biopharmaceutical and life sciences company focused on advancing cutting-edge therapies in healthcare. The Company mainly engages in developing technologies and products in oncology therapeutics and diagnostics, with a focus on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It develops therapeutics across fields in oncology and has a portfolio of products in the pipeline, including GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in different stages of development.

  • Contact

    D6 Thane Road
    MediCity Nottingham
    NottinghamNG90 6BH
    GBR

    T: +44 1157840026

    E: [email protected]

    https://www.valirx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    11

Stocks News & Analysis

stocks

Tesla: Reported China divestiture plan could clear path for SpaceX merger

Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.
stocks

This onetime AI market darling is now surprisingly undervalued

This AI leader qualifies as a GARP stock today.
stocks

Undervalued ASX miner hits production homerun

Record volumes, lower costs and reduced debt underpin a stronger earnings outlook for ASX miner.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,137.0070.20-0.76%
CAC 408,509.6424.000.28%
DAX 4025,629.2417.210.07%
Dow JONES (US)52,485.03276.970.53%
FTSE 10010,868.0529.22-0.27%
HKSE25,884.4325.550.10%
NASDAQ25,373.85251.681.00%
Nikkei 22564,362.022,494.594.03%
NZX 50 Index13,699.2863.50-0.46%
S&P 5007,489.7252.090.70%
S&P/ASX 2008,976.8073.10-0.81%
SSE Composite Index3,832.2627.570.72%

Market Movers